82 citations
,
March 2013 in “PLoS ONE” In this study, vemurafenib was associated with a wide range of cutaneous side effects in patients with advanced melanoma, including photosensitivity and various skin and hair changes, necessitating regular dermatological management.
21 citations
,
March 2015 in “Journal of The American Academy of Dermatology” In this study, five out of six patients treated with vemurafenib for metastatic melanoma experienced hair loss, which improved after topical steroid treatment.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” This case report observed vemurafenib-induced pityriasis amiantacea, a scalp scaling reaction, in a patient with metastatic melanoma, which was managed symptomatically without altering vemurafenib treatment.
4 citations
,
October 2013 in “PLoS ONE” This study found that Vemurafenib led to a broad range of cutaneous side effects in nearly all patients with advanced melanoma, highlighting the need for regular dermatologic management and UV protection.
32 citations
,
May 2016 in “European journal of dermatology/EJD. European journal of dermatology” In this study, researchers found that targeted therapies for metastatic melanoma often cause hair and nail side effects, with hair changes more common in patients treated with BRAF inhibitors like vemurafenib.